Santarus (SNTS) Tops Q3 Views
More News related to SNTS
- Santarus to Present at Piper Jaffray 21st Annual Health Care Conference
- Santarus to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Morning Movers 11/05: ROYL, RX, FSYS, KAI, SANM Higher; SMSI, CVS, MBRK, INOD, PL, ARO Lower
- After-Hours Movers 11/04: RSOL, SANM, PARL, VLNC, GIVN, CECO Higher; SMSI, AUTH, WFMI, ANDE Lower
- Santarus (SNTS) Tops Q3 Views
More News related to Earnings
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
- ZymoGenetics (ZGEN) Higher Ahead of Presentation
- Somaxon Pharmaceuticals (SOMX) Surges Ahead of FDA Action Date
- BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
Santarus, Inc. (NASDAQ: SNTS) reports Q3 EPS of $0.09, ex-items, 8 cents better than the analyst estimate of $0.01. Revenue for the quarter was $39.5 million, which compares to the estimate of $36.47 million.
Related Categories
EarningsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
